Breaking News

WuXi Biologics to Build Mfg. Center in Southwest China

Begins construction of a 48,000L Integrated Manufacturing Center for Innovative Biologics in Chengdu

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Biologics has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will house the company’s 12th drug substance manufacturing facility.   This new integrated manufacturing center will include drug development and commercial manufacturing facilities with initial bioreactor capacity of 48,000L. As the first biologics company in China passing both U.S. FDA and EMA GMP ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters